Brian Abrahams
Stock Analyst at RBC Capital
(2.21)
# 2,362
Out of 5,182 analysts
452
Total ratings
41.25%
Success rate
-5.53%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Initiates: Outperform | $52 | $28.41 | +83.03% | 1 | Mar 9, 2026 | |
| APGE Apogee Therapeutics | Maintains: Sector Perform | $83 → $82 | $84.34 | -2.77% | 4 | Mar 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $745 → $765 | $761.85 | +0.41% | 36 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Sector Perform | $12 → $13 | $17.36 | -25.12% | 5 | Mar 2, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Sector Perform | $18 → $6 | $4.30 | +39.53% | 6 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $31 → $30 | $22.20 | +35.17% | 5 | Feb 26, 2026 | |
| GLPG Galapagos NV | Maintains: Sector Perform | $32 → $33 | $29.42 | +12.17% | 14 | Feb 25, 2026 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $11 → $12 | $9.86 | +21.70% | 13 | Feb 20, 2026 | |
| PTCT PTC Therapeutics | Maintains: Sector Perform | $87 → $82 | $67.77 | +21.00% | 24 | Feb 20, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $546 → $541 | $438.71 | +23.32% | 58 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $177 | $131.60 | +34.50% | 25 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $95 → $92 | $95.93 | -4.10% | 25 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $103 → $118 | $139.71 | -15.54% | 35 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $217 → $233 | $177.34 | +31.39% | 42 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $13 | $9.02 | +44.12% | 20 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $30 | $15.51 | +93.42% | 1 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $40 | $14.57 | +174.54% | 2 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $36 | $20.68 | +74.08% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $103 | $85.40 | +20.61% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $40.49 | -40.73% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $7 | $2.00 | +250.00% | 7 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $13.44 | +63.69% | 6 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $53 | $10.17 | +421.14% | 9 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $1.5 → $1 | $0.85 | +18.08% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.35 | +48.15% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $58 | $56.85 | +2.02% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $5.89 | +222.58% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $23.23 | -0.99% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $19.14 | +338.87% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $168.51 | -15.14% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $32.99 | +21.25% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $13.14 | +14.16% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $3.79 | +137.47% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $22.45 | - | 4 | Dec 4, 2017 |
Pharvaris
Mar 9, 2026
Initiates: Outperform
Price Target: $52
Current: $28.41
Upside: +83.03%
Apogee Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $83 → $82
Current: $84.34
Upside: -2.77%
Regeneron Pharmaceuticals
Mar 2, 2026
Maintains: Sector Perform
Price Target: $745 → $765
Current: $761.85
Upside: +0.41%
MoonLake Immunotherapeutics
Mar 2, 2026
Maintains: Sector Perform
Price Target: $12 → $13
Current: $17.36
Upside: -25.12%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Sector Perform
Price Target: $18 → $6
Current: $4.30
Upside: +39.53%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $31 → $30
Current: $22.20
Upside: +35.17%
Galapagos NV
Feb 25, 2026
Maintains: Sector Perform
Price Target: $32 → $33
Current: $29.42
Upside: +12.17%
Prothena Corporation
Feb 20, 2026
Maintains: Sector Perform
Price Target: $11 → $12
Current: $9.86
Upside: +21.70%
PTC Therapeutics
Feb 20, 2026
Maintains: Sector Perform
Price Target: $87 → $82
Current: $67.77
Upside: +21.00%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Outperform
Price Target: $546 → $541
Current: $438.71
Upside: +23.32%
Feb 12, 2026
Maintains: Outperform
Price Target: $180 → $177
Current: $131.60
Upside: +34.50%
Feb 11, 2026
Maintains: Sector Perform
Price Target: $95 → $92
Current: $95.93
Upside: -4.10%
Feb 11, 2026
Maintains: Sector Perform
Price Target: $103 → $118
Current: $139.71
Upside: -15.54%
Feb 9, 2026
Maintains: Outperform
Price Target: $217 → $233
Current: $177.34
Upside: +31.39%
Jan 30, 2026
Maintains: Outperform
Price Target: $14 → $13
Current: $9.02
Upside: +44.12%
Jan 29, 2026
Maintains: Outperform
Price Target: $28 → $30
Current: $15.51
Upside: +93.42%
Jan 23, 2026
Maintains: Outperform
Price Target: $33 → $40
Current: $14.57
Upside: +174.54%
Jan 23, 2026
Maintains: Outperform
Price Target: $20 → $36
Current: $20.68
Upside: +74.08%
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $85.40
Upside: +20.61%
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $40.49
Upside: -40.73%
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $2.00
Upside: +250.00%
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $13.44
Upside: +63.69%
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $10.17
Upside: +421.14%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $0.85
Upside: +18.08%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.35
Upside: +48.15%
Nov 4, 2025
Maintains: Outperform
Price Target: $55 → $58
Current: $56.85
Upside: +2.02%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $5.89
Upside: +222.58%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $23.23
Upside: -0.99%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $19.14
Upside: +338.87%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $168.51
Upside: -15.14%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $32.99
Upside: +21.25%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $13.14
Upside: +14.16%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $3.79
Upside: +137.47%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $22.45
Upside: -